

exempting the drug from bearing adequate directions for use in its labeling; 502 (1)—the article was composed wholly or partly of tetracycline, a derivative of chlortetracycline, and it was not from a batch with respect to which a certificate or release had been issued pursuant to the law; and 503 (b) (4)—the article was subject to the provisions of 503 (b) (1), and its label failed to bear the statement "Caution: Federal law prohibits dispensing without prescription."

DISPOSITION: 4-14-55. Default—delivered to the Food and Drug Administration.

4744. *Achromycin capsules and terramycin capsules.* (F. D. C. No. 37927. S. Nos. 21-805/6 M.)

QUANTITY: 1 300-capsule btl. of *Achromycin capsules* and 2 250-capsule btls. of *terramycin capsules* at Philadelphia, Pa.

SHIPPED: 8-4-54, from Franklin Square, Long Island, N. Y., by Economy Buying Service, Inc.

RESULTS OF INVESTIGATION: Analyses showed that the *Achromycin capsules* contained 250 milligrams of tetracycline hydrochloride per capsule and that the *terramycin capsules* contained 250 milligrams of oxytetracycline hydrochloride per capsule.

LIBELED: 4-7-55, E. Dist. Pa.

CHARGE: 502 (b) (1)—the labels of the articles when shipped failed to bear the name and place of business of the manufacturer, packer, or distributor; 502 (f) (1)—the labels of the articles failed to bear adequate directions for use; 503 (b) (4)—the articles were subject to 503 (b) (1), and their labels failed to bear the statement "Caution: Federal law prohibits dispensing without prescription"; and 502 (1)—the *Achromycin capsules* purported to be and were represented as a drug composed wholly or partly of a derivative of chlortetracycline, and the capsules were not from a batch with respect to which a certificate or release had been issued pursuant to the law.

DISPOSITION: 7-27-55. Default—destruction.

4745. *Nasal hydrocortisone, nasal solution, and Aureomycin capsules.* (F. D. C. No. 37954. S. Nos. 13-661/3 M.)

QUANTITY: 7 ½-oz. vials of *nasal hydrocortisone*, 7 ½-oz. vials of *nasal solution*, and 1 100-capsule btl. of *Aureomycin capsules*, at Philadelphia, Pa.

SHIPPED: During January 1955, from Franklin Square, Long Island, N. Y., by Carl H. Kaplan, t/a Economy Buying Service, Inc.

LABEL IN PART: (Vial) "Vasocort Hydrocortisone Nasal" and "Drilitol Nasal Solution"; (btl.) "100 * * * Lederle Aureomycin Hydrochloride Crystalline Capsules 250 mg."

RESULTS OF INVESTIGATION: The *Aureomycin capsules* were shipped in a bulk container and were placed by the shipper in the above-described bottle when he delivered the capsules to the consignee, who supplied the bottle.

Partial analyses disclosed that the *nasal hydrocortisone* contained hydrocortisone and Paredrine; that the *nasal solution* contained thenylpyramine hydrochloride, Paredrine, and polymyxin B; and that the *Aureomycin capsules* contained about 155 milligrams of chlortetracycline per capsule.

LIBELED: 4-29-55, E. Dist. Pa.; amended libel filed 6-2-55.

CHARGE: 501 (b)—the *Aureomycin capsules* purported to be and were represented as a drug, the name of which is recognized in the United States Pharma-